OncoMed Provides Update on Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial

OncoMed Provides Update on Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial

REDWOOD CITY, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced an update on the Phase 2 …

(Visited 3 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.